Literature DB >> 21480322

Transcription coactivator mediator subunit MED1 is required for the development of fatty liver in the mouse.

Liang Bai1, Yuzhi Jia, Navin Viswakarma, Jiansheng Huang, Aurore Vluggens, Nathan E Wolins, Nadereh Jafari, M Sambasiva Rao, Jayme Borensztajn, Gongshe Yang, Janardan K Reddy.   

Abstract

UNLABELLED: Peroxisome proliferator-activated receptor-γ (PPARγ), a nuclear receptor, when overexpressed in liver stimulates the induction of adipocyte-specific and lipogenesis-related genes and causes hepatic steatosis. We report here that Mediator 1 (MED1; also known as PBP or TRAP220), a key subunit of the Mediator complex, is required for high-fat diet-induced hepatic steatosis as well as PPARγ-stimulated adipogenic hepatic steatosis. Mediator forms the bridge between transcriptional activators and RNA polymerase II. MED1 interacts with nuclear receptors such as PPARγ and other transcriptional activators. Liver-specific MED1 knockout (MED1(ΔLiv) ) mice, when fed a high-fat (60% kcal fat) diet for up to 4 months failed to develop fatty liver. Similarly, MED1(ΔLiv) mice injected with adenovirus-PPARγ (Ad/PPARγ) by tail vein also did not develop fatty liver, whereas mice with MED1 (MED1(fl/fl) ) fed a high-fat diet or injected with Ad/PPARγ developed severe hepatic steatosis. Gene expression profiling and northern blot analyses of Ad/PPARγ-injected mouse livers showed impaired induction in MED1(ΔLiv) mouse liver of adipogenic markers, such as aP2, adipsin, adiponectin, and lipid droplet-associated genes, including caveolin-1, CideA, S3-12, and others. These adipocyte-specific and lipogenesis-related genes are strongly induced in MED1(fl/fl) mouse liver in response to Ad/PPARγ. Re-expression of MED1 using adenovirally-driven MED1 (Ad/MED1) in MED1(ΔLiv) mouse liver restored PPARγ-stimulated hepatic adipogenic response. These studies also demonstrate that disruption of genes encoding other coactivators such as SRC-1, PRIC285, PRIP, and PIMT had no effect on hepatic adipogenesis induced by PPARγ overexpression.
CONCLUSION: We conclude that transcription coactivator MED1 is required for high-fat diet-induced and PPARγ-stimulated fatty liver development, which suggests that MED1 may be considered a potential therapeutic target for hepatic steatosis. (HEPATOLOGY 2011;).
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21480322      PMCID: PMC3076129          DOI: 10.1002/hep.24155

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  34 in total

Review 1.  Peroxisome proliferator-activated receptors: nuclear control of metabolism.

Authors:  B Desvergne; W Wahli
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

Review 2.  Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes.

Authors:  Urs A Boelsterli; Marc Bedoucha
Journal:  Biochem Pharmacol       Date:  2002-01-01       Impact factor: 5.858

3.  Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression.

Authors:  Songtao Yu; Kimihiko Matsusue; Papreddy Kashireddy; Wen-Qing Cao; Vaishalee Yeldandi; Anjana V Yeldandi; M Sambasiva Rao; Frank J Gonzalez; Janardan K Reddy
Journal:  J Biol Chem       Date:  2002-10-24       Impact factor: 5.157

4.  S3-12, Adipophilin, and TIP47 package lipid in adipocytes.

Authors:  Nathan E Wolins; Benjamin K Quaynor; James R Skinner; Marissa J Schoenfish; Anatoly Tzekov; Perry E Bickel
Journal:  J Biol Chem       Date:  2005-02-24       Impact factor: 5.157

5.  Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity.

Authors:  Yong-Xu Wang; Chih-Hao Lee; Sambath Tiep; Ruth T Yu; Jungyeob Ham; Heonjoong Kang; Ronald M Evans
Journal:  Cell       Date:  2003-04-18       Impact factor: 41.582

Review 6.  Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.

Authors:  Janardan K Reddy; M Sambasiva Rao
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-05       Impact factor: 4.052

7.  Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.

Authors:  Kimihiko Matsusue; Martin Haluzik; Gilles Lambert; Sun-Hee Yim; Oksana Gavrilova; Jerrold M Ward; Bryan Brewer; Marc L Reitman; Frank J Gonzalez
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

8.  Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes.

Authors:  Hong Wang; Li Qiang; Stephen R Farmer
Journal:  Mol Cell Biol       Date:  2007-10-22       Impact factor: 4.272

9.  Transcriptional coactivator PRIP, the peroxisome proliferator-activated receptor gamma (PPARgamma)-interacting protein, is required for PPARgamma-mediated adipogenesis.

Authors:  Chao Qi; Sailesh Surapureddi; Yi-Jun Zhu; Songtao Yu; Papreddy Kashireddy; M Sambasiva Rao; Janardan K Reddy
Journal:  J Biol Chem       Date:  2003-05-16       Impact factor: 5.157

10.  Dynamic and differential regulation of proteins that coat lipid droplets in fatty liver dystrophic mice.

Authors:  Angela M Hall; Elizabeth M Brunt; Zhouji Chen; Navin Viswakarma; Janardan K Reddy; Nathan E Wolins; Brian N Finck
Journal:  J Lipid Res       Date:  2009-09-11       Impact factor: 5.922

View more
  29 in total

Review 1.  General molecular biology and architecture of nuclear receptors.

Authors:  Michal Pawlak; Philippe Lefebvre; Bart Staels
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

2.  Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice.

Authors:  Jiansheng Huang; Yuzhi Jia; Tao Fu; Navin Viswakarma; Liang Bai; M Sambasiva Rao; Yijun Zhu; Jayme Borensztajn; Janardan K Reddy
Journal:  FASEB J       Date:  2011-10-18       Impact factor: 5.191

3.  The Med1 subunit of the mediator complex induces liver cell proliferation and is phosphorylated by AMP kinase.

Authors:  Navin Viswakarma; Yuzhi Jia; Liang Bai; Qian Gao; Bingliang Lin; Xiaohong Zhang; Parimal Misra; Ajay Rana; Sanjay Jain; Frank J Gonzalez; Yi-Jun Zhu; Bayar Thimmapaya; Janardan K Reddy
Journal:  J Biol Chem       Date:  2013-08-13       Impact factor: 5.157

4.  Cardiac Med1 deletion promotes early lethality, cardiac remodeling, and transcriptional reprogramming.

Authors:  Kathryn M Spitler; Jessica M Ponce; Gavin Y Oudit; Duane D Hall; Chad E Grueter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-02-03       Impact factor: 4.733

Review 5.  Endocrine-disrupting chemicals and fatty liver disease.

Authors:  Charles E Foulds; Lindsey S Treviño; Brian York; Cheryl L Walker
Journal:  Nat Rev Endocrinol       Date:  2017-05-19       Impact factor: 43.330

Review 6.  Transcriptional coregulators: fine-tuning metabolism.

Authors:  Laurent Mouchiroud; Lillian J Eichner; Reuben J Shaw; Johan Auwerx
Journal:  Cell Metab       Date:  2014-05-01       Impact factor: 27.287

7.  Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice.

Authors:  Abigail Wolf Greenstein; Neena Majumdar; Peng Yang; Papasani V Subbaiah; Rhonda D Kineman; Jose Cordoba-Chacon
Journal:  J Endocrinol       Date:  2016-10-31       Impact factor: 4.286

8.  Progressive endoplasmic reticulum stress contributes to hepatocarcinogenesis in fatty acyl-CoA oxidase 1-deficient mice.

Authors:  Jiansheng Huang; Navin Viswakarma; Songtao Yu; Yuzhi Jia; Liang Bai; Aurore Vluggens; Mustapha Cherkaoui-Malki; Mushfiquddin Khan; Inderjit Singh; Gongshe Yang; M Sambasiva Rao; Jayme Borensztajn; Janardan K Reddy
Journal:  Am J Pathol       Date:  2011-06-12       Impact factor: 4.307

9.  The Mediator Complex and Lipid Metabolism.

Authors:  Yi Zhang; Xiaoping Zhao; Fajun Yang
Journal:  J Biochem Pharmacol Res       Date:  2013-03

10.  Dual Outcomes of Rosiglitazone Treatment on Fatty Liver.

Authors:  Mingming Gao; Yongjie Ma; Mohammad Alsaggar; Dexi Liu
Journal:  AAPS J       Date:  2016-04-28       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.